+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viral Clearance - Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4806194
The global market for Viral Clearance was estimated at US$566.2 Million in 2023 and is projected to reach US$1.8 Billion by 2030, growing at a CAGR of 18.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Recombinant Proteins Application segment, which is expected to reach US$430.4 Million by 2030 with a CAGR of a 18.6%. The Blood and Blood Products Application segment is also set to grow at 16% CAGR for the next 7-year period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $178.6 Million in 2023, and China, forecasted to grow at an impressive 17.9% CAGR to reach $319.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Viral Clearance Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Viral Clearance Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Viral Clearance Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Avance Biosciences Inc., BSL BIOSERVICE Scientific Laboratories Munich GmbH, Charles River Laboratories International, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 41 Featured):

  • Avance Biosciences Inc.
  • BSL BIOSERVICE Scientific Laboratories Munich GmbH
  • Charles River Laboratories International, Inc.
  • Clean Cells Inc.
  • Lonza Group AG
  • Merck KgaA
  • SGS SA
  • Sigma-Aldrich Corporation
  • Texcell, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Viral Clearance - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World 7-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 4: World 7-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Blood and Blood Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World 7-Year Perspective for Blood and Blood Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World 7-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 10: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World 7-Year Perspective for Pharmaceutical & Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 14: World 7-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 16: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 19: World Viral Clearance Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 22: USA Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 23: USA 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
CANADA
  • TABLE 24: Canada Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Canada 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Canada 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
JAPAN
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 28: Japan Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Japan 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 30: Japan Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 31: Japan 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
CHINA
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 32: China Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: China 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 34: China Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 35: China 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
EUROPE
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 36: Europe Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 37: Europe 7-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Europe 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 40: Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 41: Europe 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
FRANCE
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 42: France Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 43: France 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 44: France Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: France 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
GERMANY
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 46: Germany Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Germany 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 48: Germany Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Germany 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
ITALY
  • TABLE 50: Italy Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Italy 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 52: Italy Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 53: Italy 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
UNITED KINGDOM
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 54: UK Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 55: UK 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 56: UK Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: UK 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
REST OF EUROPE
  • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 59: Rest of Europe 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 61: Rest of Europe 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
ASIA-PACIFIC
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Asia-Pacific 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Asia-Pacific 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
REST OF WORLD
  • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 67: Rest of World 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • TABLE 68: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Rest of World 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Avance Biosciences Inc.
  • BSL BIOSERVICE Scientific Laboratories Munich GmbH
  • Charles River Laboratories International, Inc.
  • Clean Cells Inc.
  • Lonza Group AG
  • Merck KgaA
  • SGS SA
  • Sigma-Aldrich Corporation
  • Texcell, Inc.

Table Information